[2-(4-chlorophenylcarbamoyl)-phenyl]carbamic acid tert-butyl ester | 618359-42-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [2-(4-chlorophenylcarbamoyl)-phenyl]carbamic acid tert-butyl ester
• CAS: 618359-42-5
• 化学式: C₁₈H₁₉ClN₂O₃
• 分子量: 346.813
• InChiKey: XMODXTGCGCGUTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.94
• 重原子数：
  24.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  67.43
• 氢给体数：
  2.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  [2-(4-chlorophenylcarbamoyl)-phenyl]carbamic acid tert-butyl ester 在 盐酸 、 溶剂黄146 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 5.5h， 生成 N-(4-Chloro-phenyl)-2-{[1-pyridin-4-yl-meth-(E)-ylidene]-amino}-benzamide
  参考文献：
  名称：

  Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching

  摘要：

  The vascular endothelial growth factor (VEGF) tyrosine kinase receptors KDR and Flt-1 are targets of current interest in anticancer drug research. PTK787/ZK222584 is a potent inhibitor of these enzymes in clinical evaluation as an antiangiogenic agent. The development of a hypothesis concerning the bioactive conformation of this compound has led to the discovery of a new class of potent inhibitors of KDR and Flt-1, the anthranilamides. This could be achieved with a limited experimental effort, which only involved the testing of one archive compound and the synthesis and testing of one appropriate analogue. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00626-7
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 N-甲基吗啉 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 [2-(4-chlorophenylcarbamoyl)-phenyl]carbamic acid tert-butyl ester
  参考文献：
  名称：

  Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching

  摘要：

  The vascular endothelial growth factor (VEGF) tyrosine kinase receptors KDR and Flt-1 are targets of current interest in anticancer drug research. PTK787/ZK222584 is a potent inhibitor of these enzymes in clinical evaluation as an antiangiogenic agent. The development of a hypothesis concerning the bioactive conformation of this compound has led to the discovery of a new class of potent inhibitors of KDR and Flt-1, the anthranilamides. This could be achieved with a limited experimental effort, which only involved the testing of one archive compound and the synthesis and testing of one appropriate analogue. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00626-7